TI
PGNX

Trexquant Investment’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Trexquant Investment’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-35,008
Closed -$281K – 1304
2018
Q2 		$281K Buy
+35,008
New +$267K 0.02% 701
2015
Q4 		– Sell
-10,918
Closed -$62K – 1377
2015
Q3 		$62K Buy
+10,918
New +$83.8K 0.01% 996
2015
Q2 		– Sell
-152,400
Closed -$911K – 1344
2015
Q1 		$911K Buy
152,400
+127,400
+510% +$802K 0.09% 413
2014
Q4 		$189K Buy
+25,000
New +$150K 0.03% 820

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Trexquant Investment's PGNX Position: Q3 2018 in Review

Trexquant Investment sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 35,008 shares — an estimated $281K sold.

Trexquant Investment first reported a position in PGNX in Q4 2014 and held it in 4 quarters. The position peaked at $911K in Q1 2015. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Trexquant Investment reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Trexquant Investment sold 35,008 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $281K.
  • Trexquant Investment first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 4 quarters.
  • Trexquant Investment's Progenics Pharmaceuticals Inc position peaked at $911K in Q1 2015.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Trexquant Investment's 13F filing for Q3 2018, filed 9 Nov 2018.